Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Akeso, Inc.
康方生物科技（開曼）有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

AK112–309/HARMONI-GI1 MET PRIMARY ENDPOINT OF OS IVONESCIMAB PLUS CHEMO DEMONSTRATES STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL OS BENEFIT VERSUS DURVALUMAB PLUS CHEMO IN 1L BTC

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that its global first-in-class PD-1/VEGF bispecific antibody, ivonescimab plus chemo demonstrates significant overall survival (OS) benefit versus durvalumab (PD-L1) plus chemo in the randomized, controlled, double-blinded, multicenter, registrational Phase III clinical study (AK112–309/HARMONi-GI1) for the first-line treatment of advanced biliary tract cancer (BTC). The Independent Data Monitoring Committee (IDMC) declared that the pre-specified interim analysis of this study met its primary endpoint of overall survival (OS), achieving a statistically significant and clinically meaningful positive result; the study met all key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).

Detailed results from this study will be presented at an upcoming international academic conference.

The study enrolled a total of 682 patients. Baseline characteristics were consistent with real-world clinical practice and well balanced between the treatment and control arms.

The positive result of HARMONi-GI1 marks the first positive Phase III study for ivonescimab in gastrointestinal tumors, following four positive Phase III results in lung cancer. The breakthrough clinical value of ivonescimab is now expanding from lung cancer to a broader range of solid tumors.

ABOUT HARMONI-GI1/AK112–309

HARMONi-GI1/AK112–309 (CTR20243164) is a randomized, controlled, multicenter Phase III clinical trial evaluating ivonescimab in combination with chemotherapy versus durvalumab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer. The primary endpoint is overall survival (OS), and the key secondary endpoints are progression-free survival (PFS) and objective response rate (ORR) as assessed by investigators per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). The HARMONi-GI1 study enrolled a total of 682 participants.

ABOUT依達方® (IVONESCIMAB, PD-1/VEGF)

依達方® (ivonescimab, PD-1/VEGF) is a novel global first-in-class PD-1/VEGF bi-specific immunotherapy drug independently developed by the Company. On May 24, 2024, 依達方® was granted marketing approval by NMPA for the treatment of EGFR mutated locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment. On April 25, 2025, the sNDA of ivonescimab as first-line treatment for locally advanced or metastatic NSCLC with PD-L1 positive expression was approved. The above two indications have been included in the latest National Reimbursement Drug List. On August 12, 2026, the sNDA of ivonescimab as first-line treatment of squamous NSCLC was approved. The Company is conducting over 60 Phase II/III clinical trials of ivonescimab covering over 40 indications including lung cancer, biliary tract cancer, head and neck squamous carcinoma, triple negative breast cancer, colorectal cancer, pancreatic cancer, and urothelial cancer. Currently, 16 registrational Phase II/III trials of ivonescimab are ongoing.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive Director

Hong Kong, August 26, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive Directors, Mr. XIE Ronggang as non-executive Director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.